Skip to main content
SearchLoginLogin or Signup

Reviews of "A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability"

Reviewers: Thomas Demoulins (University of Bern) | 📘📘📘📘📘 • Hamid Niknam, Nastaran Savar (Pasteur Institute of Iran) | 📒📒📒◻️◻️ • Rushit N. Lodaya, Derek T. O'Hagan (Rockville Center for Vaccines) | 📒📒📒◻️◻️ • Cristian Smerdou (Cima Universidad de Navarra) | 📘📘📘📘📘

Published onApr 16, 2022
Reviews of "A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability"
key-enterThis Pub is a Review of
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
Description

ABSTRACTmRNA vaccines were the first to be authorized for use against SARS-CoV-2 and have since demonstrated high efficacy against serious illness and death. However, limitations in these vaccines have been recognized due to their requirement for cold storage, short durability of protection, and lack of access in low-resource regions. We have developed an easily-manufactured, potent self-amplifying RNA (saRNA) vaccine against SARS-CoV-2 that is stable at room temperature. This saRNA vaccine is formulated with a nanostructured lipid carrier (NLC), providing enhanced stability, improved manufacturability, and protection against degradation. In preclinical studies, this saRNA/NLC vaccine induced strong humoral immunity, as demonstrated by high pseudovirus neutralization titers to the Alpha, Beta, and Delta variants of concern and induction of long-lived bone marrow-resident antibody secreting cells. Robust Th1-biased T-cell responses were also observed after prime or homologous prime-boost in mice. Notably, the saRNA/NLC platform demonstrated thermostability at room temperature for at least 6 months when lyophilized. Taken together, this saRNA delivered by NLC represents a potential improvement in RNA technology that could allow wider access to RNA vaccines for the current COVID-19 and future pandemics.

To read the original manuscript, click the link above.

Summary of Reviews: This preprint provides a proof-of-concept demonstration for a new COVID-19 vaccine that can be stored at room temperature. Reviewers noted that though the evidence generally justifies the main claim, more work is needed to use this as an alternative to existing licensed vaccines.

Reviewer 1 (Thomas Demoulins) | 📘📘📘📘📘

Reviewer 2 (Hamid Mahmoudzadeh Niknam & Nastaran Sadat Savar) | 📒📒📒 ◻️◻️

Reviewer 3 (Rushit N. Lodaya & Derek T. O’Hagan) | 📒📒📒 ◻️◻️

Reviewer 4 (Cristian Smerdou) | 📘📘📘📘📘

RR:C19 Strength of Evidence Scale Key

📕 ◻️◻️◻️◻️ = Misleading

📙📙 ◻️◻️◻️ = Not Informative

📒📒📒 ◻️◻️ = Potentially Informative

📗📗📗📗◻️ = Reliable

📘📘📘📘📘 = Strong

To read the reviews, click the links below. 

Connections
1 of 4
Comments
0
comment

No comments here

Why not start the discussion?